Reference tiers only. Track the dose you are already taking.
FOR Easing in or milder cases
BENEFIT Often picked as the lower-exposure tier in nerve and inflammation research
FOR The common dose for nerve discomfort
BENEFIT The studied range most often cited in ARA-290 discussions
FOR Stubborn neuropathy, short term
BENEFIT A higher-exposure tier discussed in persistent neuropathy research
Schedule: Daily for a set block of 4 to 12 weeks.
Beginner ramp: Start at the standard dose, adjust by response.
Ranges are reference only, not a recommendation. See Sources & research below.